Skip to Content

Alfuzosin Pregnancy and Breastfeeding Warnings

Alfuzosin is also known as: Uroxatral

Medically reviewed on January 29, 2018

Alfuzosin Pregnancy Warnings

Animal data have failed to reveal evidence of teratogenicity or embryotoxicity at maternal doses up to 250 mg/kg/day. There are no approved indications for use of this drug in females.

AU TGA pregnancy category B2: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals are inadequate or may be lacking, but available data show no evidence of an increased occurrence of fetal damage.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

This drug is not indicated for use in female patients.

AU TGA pregnancy category: B2
US FDA pregnancy category: B

See references

Alfuzosin Breastfeeding Warnings

This drug is not indicated for use in female patients.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

See references

References for pregnancy information

  1. "Product Information. Uroxatral (alfuzosin)." sanofi-aventis , Bridgewater, NJ.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.

References for breastfeeding information

  1. "Product Information. Uroxatral (alfuzosin)." sanofi-aventis , Bridgewater, NJ.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide